Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$24.58 USD
-0.11 (-0.45%)
Updated May 3, 2024 04:00 PM ET
After-Market: $24.58 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.58 USD
-0.11 (-0.45%)
Updated May 3, 2024 04:00 PM ET
After-Market: $24.58 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Zacks News
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
by Zacks Equity Research
Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.
Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up
by Zacks Equity Research
Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9%.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates
by Kinjel Shah
Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.
Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 146.3% upside potential for Bicycle Therapeutics PLC Sponsored ADR (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bicycle (BCYC) up on Collaboration With Novartis for Conjugates
by Zacks Equity Research
Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ionis (IONS) Q2 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Ionis (IONS) incurs wider-than-expected Q2 loss. The company maintains its sales guidance for 2021 but expects to incur more losses.
Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View
by Zacks Equity Research
Following a positive recovery from COVID-impacts, Alkermes (ALKS) beat both earnings and sales estimates in second-quarter 2021. The company also raised its guidance for 2021.
Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View
by Zacks Equity Research
Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021. Resultantly, the stock rises.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Is a Great Choice for "Trend" Investors, Here's Why
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe
by Zacks Equity Research
Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.
Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval
by Zacks Equity Research
Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs
by Zacks Equity Research
Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.
Here's What Could Help Bicycle Therapeutics PLC Sponsored ADR (BCYC) Maintain Its Recent Price Strength
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bicycle Therapeutics (BCYC) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Bicycle Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Bicycle Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Has Bicycle Therapeutics PLC Sponsored (BCYC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BCYC) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for March 16th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 16th.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Bicycle Therapeutics PLC Sponsored (BCYC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BCYC) Outperforming Other Medical Stocks This Year?